Introduction {#S1}
============

Parkinson's disease (PD) is a common neurodegenerative disease and is expected to affect 14.2 million people worldwide by 2040 ([@B15]). Its typical clinical features are motor symptoms, which result from accumulated Lewy bodies and the remarkable death of dopaminergic neurons in the substantia nigra pars compacta (SNpc). In addition, Parkinson's disease is correlated with many non-motor symptoms, some of which even precede the motor symptoms by more than 10 years, including constipation, hyposmia, anxiety, depression, and rapid eye movement sleep behavior disorder ([@B17]). These non-motor symptoms are probably due to the disturbance of various neurotransmitters and multiple nerve systems in addition to the dopaminergic neurons in the SNpc ([@B32]). Most idiopathic PD patients are sporadic, and various environmental exposures have been identified as being correlated with the development of PD. Results of genome-wide association studies have also identified 90 independent mutations in more than 20 genes that increase risk factors for Parkinson's disease ([@B3]). Therein, the strongest genetic risk factor is the Asn370Ser mutation of β-glucocerebrosidase, with an odds ratio greater than 5 ([@B37]). The interactions between environmental and genetic risk factors are still under investigation.

Drugs that increase intracerebral dopamine levels or directly stimulate dopamine receptors remain as the most common forms of treatment for PD patients ([@B6]). These drugs are mainly for symptomatic treatment without neuroprotection or a so-called disease-modifying function. Researchers have found that mitochondrial oxidative stress and inflammation reaction play important roles in the apoptosis of dopaminergic neurons during the occurrence and development of Parkinson's disease ([@B41]). However, drugs targeting oxidative stress have exhibited little therapeutic benefit ([@B40]). Research also indicates that Parkinson's disease is related to the dysregulation of protein homeostasis, including intracellular and membrane protein trafficking, protein aggregation, and protein degradation by the ubiquitin-proteasome or lysosome-autophagy systems ([@B8]). Thus, the potential pathogenesis should be clarified and more effective disease-modifying treatments are urgently needed for PD patients.

Metabolomics is a comprehensive assessment of the total endogenous metabolites in a biological system, and proteomics can evaluate alterations at the protein level ([@B34]). These omics data can help researchers make many discoveries in the alteration of molecules and metabolic pathways following gene expression in PD patients. Plasma is an easily obtainable, non-invasive, and informative biofluid from patients, making it perfect to explore the pathogenesis of many neuropsychiatric disorders ([@B22]). Herein, we employed untargeted metabolomics and proteomics analysis to identify molecular changes in PD patients. Furthermore, an integrated bioinformatic analysis was performed to explore the probable pathogenesis of PD based on the above findings ([@B13]).

Materials and Methods {#S2}
=====================

Objects {#S2.SS1}
-------

Parkinson's disease patients were consecutively recruited from April 2016 to February 2017 in the Department of Neurology, the First Affiliated Hospital of Chongqing Medical University, according to the criteria reported in a previous research ([@B11]). The inclusion criteria was: (i) PD patients diagnosed using the European Federation of Neurological Societies and the International Parkinson Movement Disorder Society's European Section ([@B2]), and (ii) patients only taking dopamine analogs or dopamine receptor agonists. The exclusion criteria was: (i) those with secondary Parkinson's disease or Parkinson-plus syndrome; (ii) patients suffering from tumor, heart failure, chronic obstructive pulmonary disease, nephritis, infectious diseases, or any other severe chronic disease at the time of enrollment; and (iii) any history of stroke, brain surgery, head trauma, motor neuro disease, Alzheimer's disease, or mental diseases.

A same amount of age- and sex-matched healthy controls (HCs) were included from the Department of Physical Examination. The controls were also without any history of illness in the central nervous system or suffering from any other severe disease. This study was approved by the ethics committee of the First Affiliated Hospital of Chongqing Medical University and performed in accordance with the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study. Clinical data, metabolomics analysis, and proteomics analysis were blindly assessed or performed ([@B10]).

Clinical Data {#S2.SS2}
-------------

The clinical data of all included participants were collected. Fasting plasma samples were obtained with an EDTA-K2 tube in the morning, and then stored at -80°C until experimental analysis. All the clinical scales were assessed by experienced neurologists. Statistical analyses were performed using Statistic Package for the Social Sciences 22.0 (IBM, Armonk, NY, United States). Categorical data are exhibited as absolute numbers while continuous data are exhibited as mean ± standard error. All the clinical data were compared between PD and HC groups using Pearson *Chi*-squared tests or Fisher exact tests for categorical data and Mann--Whitney *U*-tests with Bonferroni *post hoc* tests for continuous data, as appropriate ([@B12]).

Metabolomics Analysis {#S2.SS3}
---------------------

We adopted a Waters UPLC I-class system equipped with a binary solvent delivery manager (Waters Corporation, Milford, United States) to perform the untargeted liquid chromatography-mass spectrometry-based metabolomics (thirty-six objects per group); the detailed procedure was described in a previous research ([@B13]). After that, data sets including m/z, peak retention time, and peak intensity of each ion were obtained. The m/z-peak retention time pairs were used to identify each ion based on Metlin^[1](#footnote1){ref-type="fn"}^ and Human Metabolome Database (HMDB)^[2](#footnote2){ref-type="fn"}^ while the peak intensity was deemed as the level of a metabolite. The data sets were further reduced by removing any peaks with a missing value in more than 60% of the total samples.

The positive and negative peak data were merged and multivariate statistical analyses were performed by the SIMCA-P 13.0 software package (Umetrics, Umeå, Sweden). The partial least squares-discriminant analysis (PLS-DA) model was constructed to show statistical differences and identify metabolites differentially expressed between PD patients and healthy controls, and this model was further validated by a permutation test with 200 iterations. Metabolites with variable influence on projection values (obtained from the PLS-DA model) of greater than 1.0, fold change values of greater than ±2, and *p*-values of less than 0.05 ([@B14]) were identified to be differentially expressed. These differentially expressed metabolites were then classified by chemical taxonomy based on the HMDB database, and metabolic pathway analysis was further performed by MetaboAnalyst 4.0^[3](#footnote3){ref-type="fn"}^ ([@B5]).

Proteomics Analysis {#S2.SS4}
-------------------

The plasma of twenty-seven randomized healthy controls and thirty randomized PD patients were merged into three pooled samples for proteomics analysis. The details of the proteomics analysis have also been depicted previously ([@B13]). Afterward, tandem mass spectrometry spectra were obtained and searched using the MASCOT engine 2.2 (Matrix Science, London, United Kingdom). The differentially expressed proteins were recognized by fold change values of greater than ±1.2 and *p*-values of less than 0.05. Gene ontology (GO) enrichment from cellular component, molecular function, and biological process, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed by Fisher's exact test, considering the whole quantified protein annotations as the background data set. The obtained *p*-values from enrichment analysis was further converted into *q*-value using Benjamini-Hochberg correction and a *q*-value less than 0.05 was considered significant ([@B21]).

Results {#S3}
=======

Results of the Metabolomics Analysis {#S3.SS1}
------------------------------------

Thirty-six PD patients and healthy controls were separately included in the metabolomics analysis. The clinical data of these participants are shown in [Table 1](#T1){ref-type="table"}. No significant differences were observed between these two groups, including the levels of hemoglobin A1C (HbA1C) and blood lipid, or the incidences of diabetes mellitus and hypercholesterolemia. The mean UPDRS score and Hoehn--Yahr score of these PD patients were 41.11 ± 3.72 and 2.26 ± 0.17, respectively.

###### 

Clinical data of PD patients and healthy controls included in the untargeted liquid chromatography-mass spectrometry-based metabolomics analysis.

  Variable (SEM/%)           HC (36)        PD (36)        *p*-value   Variable (SEM/%)   HC (36)          PD (36)          *p*-value
  -------------------------- -------------- -------------- ----------- ------------------ ---------------- ---------------- -----------
  Age (year)                 62.16 ± 1.73   64.03 ± 0.95   0.348       HbA1c (%)          6.17 ± 0.20      6.08 ± 0.14      0.689
  Gender, Male (%)           18 (50%)       18 (50%)       1           TC (mmol/L)        4.42 ± 0.12      4.53 ± 0.13      0.516
  Smoking history (%)        10 (27.8%)     9 (25.0%)      0.789       TG (mmol/L)        1.53 ± 0.09      1.44 ± 0.13      0.6
  Alcohol consumption (%)    2 (5.6%)       2 (5.6%)       1           HDL-C (mmol/L)     1.30 ± 0.06      1.33 ± 0.06      0.794
  Hypertension (%)           15 (46.9%)     17 (53.1%)     0.617       LDL-C (mmol/L)     2.87 ± 0.12      2.91 ± 0.11      0.816
  Diabetes mellitus (%)      4 (12.5%)      8 (25.0%)      0.2         Apo-A1 (g/L)       1.37 ± 0.04      1.34 ± 0.04      0.658
  Hypercholesterolemia (%)   12 (37.5%)     9 (28.1%)      0.424       Apo-B (g/L)        0.91 ± 0.04      0.91 ± 0.04      0.992
  BMI (kg/m2)                24.21 ± 0.57   23.00 ± 0.64   0.169       Lpa (mg/L)         190.76 ± 42.32   279.53 ± 57.03   0.216
  UPDRS score                /              41.11 ± 3.72   /           Hoehn-Yahr score   /                2.26 ± 0.17      /

PD, Parkinson's disease; SEM, standard error of the mean; HC, healthy control; HbA1c, hemoglobin A1c; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Apo-A1, apolipoprotein A1; Apo-B, apolipoprotein B; BMI, body mass index; Lpa, lipoprotein a; UPDRS, Unified Parkinson's Disease Rating Scale.

After excluding internal standards, 6040 positive and 4363 negative peaks were detected in almost 98.81% of samples on average ([Supplementary Table S1](#TS1){ref-type="supplementary-material"}). Based on the above peaks, the PLS-DA score plot showed a significant difference between the PD and HC groups (R^2^X = 0.132, R^2^Y = 0.374, Q^2^ = 0.2) ([Figure 1A](#F1){ref-type="fig"}). A permutation test with 200 iterations was performed and confirmed that the PLS-DA model was valid and not over-fitted because the original right R^2^ and Q^2^ values were observably higher than the corresponding permutated left values \[*R*^2^ = (0.0, 0.746), *Q*^2^ = (0.0, -0.198)\] ([Figure 1B](#F1){ref-type="fig"}). According to the above results, eighty-three metabolites were differentially expressed between these two groups ([Table 2](#T2){ref-type="table"}). Of these, 63% were lipid and lipid-like molecules, 13% were organic acids and derivatives, 6% were phenylpropanoids and polyketides, 5% were organic oxygen compounds, 5% were organoheterocyclic compounds, 4% were benzenoids, 2% were nucleosides, nucleotides, and analogs, 1% was homogeneous non-metal compounds, and 1% was organosulfur compounds ([Figure 1C](#F1){ref-type="fig"}). The lipid and lipid-like molecules were further categorized into sphingolipids (25%), glycerophospholipids (16%), glycerolipids (17%), fatty acyls (15%), prenol lipids (15%), and steroids and steroid derivatives (12%) ([Figure 1D](#F1){ref-type="fig"}). These sphingolipids were ganglioside GD3 (d18:0/18:0), PS\[15:0/20:4(8Z,11Z,14Z,17Z)\], camellianin D, ceramide (d18:1/16:0), adrenorphin, ganglioside GD1a (d18:0/22:0), SM(d18:0/24:1(15Z)(OH)), thiamine(1+) diphosphate(1-), N-docosahexaenoyl phenylalanine, ganglioside GA2 (d18:1/12:0), SM(d18:0/22:0), glucosylceramide (d18:1/18:0), and AS 1--5.

###### 

Key differentially expressed metabolites identified by untargeted liquid chromatography-mass spectrometry-based metabolomics analysis between PD patients and healthy control.

  Compound Name                                                                                                 Compound ID^a^   m/z value   RT (min)   Ion mode   FC value^bc^   VIP value^c^   -log(*p-value*)^c^
  ------------------------------------------------------------------------------------------------------------- ---------------- ----------- ---------- ---------- -------------- -------------- --------------------
  Coenzyme A                                                                                                    HMDB0001423      750.0117    7.6840     Positive   0.4323         2.4685         5.292
  Ganglioside GD3 (d18:0/18:0)                                                                                  HMDB0011859      737.8448    2.9037     Positive   2.4947         2.1712         6.520
  PS(15:0/20:4(8Z,11Z,14Z,17Z))                                                                                 HMDB0012312      752.4899    7.6840     Positive   0.4153         2.5890         5.192
  4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol                                                                 HMDB0030032      419.2401    3.8761     Positive   0.4434         2.0036         2.761
  Lupulone                                                                                                      HMDB0030041      829.5719    2.8968     Positive   2.1749         2.4401         8.216
  S-(Hydroxymethyl)glutathione                                                                                  HMDB0004662      113.3748    8.8773     Positive   2.5248         1.5340         3.835
  Glycinoprenol 11                                                                                              HMDB0002003      737.7329    2.8968     Positive   2.4538         2.2782         7.317
  TG(24:0/15:0/o-18:0)                                                                                          HMDB47052        919.9253    2.9037     Positive   2.1137         1.8444         5.140
  Camellianin D                                                                                                 HMDB0011920      620.4129    7.7665     Positive   0.4853         2.5231         5.238
  Dipiperamide C                                                                                                HMDB0034617      539.2666    1.9177     Positive   3.8676         1.1403         1.496
  DG(24:0/24:0/0:0)                                                                                             HMDB0007818      758.0465    9.2399     Positive   2.0050         1.0010         1.418
  Iodide                                                                                                        HMDB0012238      65.4523     8.6504     Positive   2.4751         1.4282         1.689
  TG\[24:1(15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/ 18:4(6Z,9Z,12Z,15Z)\]                                                  HMDB52343        947.7935    2.9037     Positive   2.2586         2.3058         7.459
  PC\[DiMe(11,3)/DiMe(13,5)\]                                                                                   HMDB0013456      922.6604    10.4327    Positive   2.2255         1.1533         1.568
  Lucidenic acid M                                                                                              HMDB0035973      925.5913    9.7743     Positive   3.0668         1.6801         3.860
  Pangamic acid                                                                                                 HMDB0029949      900.5774    9.5886     Positive   2.1275         1.4546         3.466
  Ceramide (d18:1/16:0)                                                                                         HMDB0004949      520.5085    8.7673     Positive   2.6757         1.8323         4.813
  Tyramine                                                                                                      HMDB0000306      69.5751     8.6504     Positive   2.1723         1.4084         1.849
  Adrenorphin                                                                                                   HMDB0012081      948.5108    2.9037     Positive   2.5786         2.4955         8.273
  Phenylacetyl-CoA                                                                                              HMDB0006503      886.1336    9.9806     Positive   2.4328         1.2223         2.087
  TG\[22:1(13Z)/22:2(13Z,16Z)/o-18:0\]                                                                          HMDB51764        947.9373    2.8968     Positive   2.1808         2.4274         8.070
  Ganglioside GD1a (d18:0/22:0)                                                                                 HMDB0011784      948.0813    2.9037     Positive   2.2465         2.4118         7.750
  Kyotorphin                                                                                                    HMDB0005768      675.3525    8.1291     Positive   2.2765         1.4563         3.057
  Kerdlan                                                                                                       HMDB0240277      853.6624    10.4396    Positive   2.0973         1.1777         1.769
  Threoninyl-Glutamine                                                                                          HMDB0029059      495.2411    1.8902     Positive   4.7886         1.1971         1.612
  TG\[18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/ 18:4(6Z,9Z,12Z,15Z)\]                                    HMDB0035640      883.6234    9.9875     Positive   2.5544         1.2463         2.114
  SM\[d18:0/24:1(15Z)(OH)\]                                                                                     HMDB0013469      829.6815    9.7674     Positive   2.5075         1.5106         3.333
  3-Methylglutaconyl-CoA                                                                                        HMDB0001057      858.0995    9.5886     Positive   2.4345         1.1968         2.040
  Dynorphin A (6-8)                                                                                             HMDB0012932      887.6266    9.9737     Positive   2.1618         1.3347         2.575
  Thiamine(1+) Diphosphate(1−)                                                                                  HMDB0011854      875.9981    6.9452     Positive   2.0855         1.1272         2.154
  LysoPC\[16:1(9Z)/0:0\]                                                                                        HMDB0010383      987.6122    9.7674     Positive   2.8140         1.4239         2.992
  Dihydroceramide                                                                                               HMDB0006752      686.6043    10.0268    Positive   2.6827         1.3579         2.580
  D-Urobilinogen                                                                                                HMDB0004158      591.3161    3.4380     Positive   2.4318         1.1614         1.396
  N-Docosahexaenoyl phenylalanine                                                                               HMDB0006482      951.6668    10.4396    Positive   2.2063         1.3591         2.418
  Alanyl-Asparagine                                                                                             HMDB0028682      407.1886    1.8211     Positive   4.3023         1.2642         1.676
  MG\[0:0/22:4(7Z,10Z,13Z,16Z)/0:0\]                                                                            HMDB0011554      840.6408    9.9875     Positive   2.7493         1.3265         2.430
  Iopromide                                                                                                     HMDB0001493      814.1201    9.5886     Positive   2.3465         1.3392         2.809
  Taraxacoside                                                                                                  HMDB0030055      797.2583    10.1989    Positive   2.3652         1.5763         3.144
  Elaidic carnitine                                                                                             HMDB0006464      851.7010    10.5890    Positive   2.0474         1.0989         1.502
  10-Hydroxy-2,8-decadiene-4,6-diynoic acid                                                                     HMDB0031054      177.0544    1.6216     Positive   0.0001         2.2388         4.311
  PE-NMe\[18:3(6Z,9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)\]                                                         HMDB0009281      400.7789    9.4806     Positive   2.1062         1.7956         4.829
  Mandelic acid                                                                                                 HMDB0000703      153.0546    1.6216     Positive   0.0078         2.3686         4.793
  Sesaminol 2-O-triglucoside                                                                                    HMDB0029556      831.2494    10.1989    Positive   2.2506         1.6307         3.334
  Polyporusterone C                                                                                             HMDB0000138      953.6222    10.1989    Positive   2.0235         1.5423         3.039
  Ganglioside GA2 (d18:1/12:0)                                                                                  HMDB0004888      991.6073    9.7537     Positive   2.0988         1.3269         2.273
  Glucoconringiin                                                                                               HMDB0001197      810.1524    9.9806     Positive   2.1748         1.4005         2.739
  Mannosyl-(N-acetylglucosaminyl)2-diphosphodolichol                                                            HMDB0012255      919.6318    9.7605     Positive   2.7027         1.6124         3.791
  3-phenylprop-2-enoic acid                                                                                     HMDB0000567      149.0597    1.6216     Positive   0.0047         2.3643         4.806
  SM(d18:0/22:0)                                                                                                HMDB0012091      789.6817    10.1989    Positive   2.3198         1.2248         2.279
  Alpha-linolenyl carnitine                                                                                     HMDB0006319      843.6455    9.9806     Positive   2.2240         1.4152         2.813
  Perulactone B                                                                                                 HMDB0030119      977.6050    10.1989    Positive   2.8190         1.5222         2.913
  PE\[DiMe(11,3)/DiMe(13,5)\]                                                                                   HMDB0008682      880.5994    9.8293     Positive   2.0844         1.7057         4.208
  Ebastine                                                                                                      HMDB0035995      939.6535    10.4327    Positive   2.2330         1.2181         1.702
  TG\[18:3(6Z,9Z,12Z)/18:4(6Z,9Z,12Z,15Z)/18:3(6Z,9Z,12Z)\]                                                     HMDB0010470      871.6774    10.4396    Positive   2.1182         1.2193         1.698
  7-chloro-2-(3,4-dimethoxyphenyl)-3,5,6-trihydroxy-8-methoxy-4H-chromen-4-one                                  HMDB0001484      816.1138    9.5955     Positive   2.0290         1.2475         2.113
  (3beta,5alpha,9alpha,22E,24R)-5,9-Epidioxy-3-hydroxyergosta-7,22-dien-6-one                                   HMDB0032666      885.6326    10.1989    Positive   2.1876         1.5669         3.119
  Cholesterol sulfate                                                                                           HMDB0000653      931.6238    10.2009    Negative   2.3774         1.5823         3.259
  Methylimidazole acetaldehyde                                                                                  HMDB0004181      371.1829    3.3773     Negative   0.4504         2.1379         2.501
  Vanillactic acid                                                                                              HMDB0000913      211.0608    1.8145     Negative   0.0027         2.4279         4.091
  PC\[14:1(9Z)/22:2(13Z,16Z)\]                                                                                  HMDB0007921      764.5535    10.0221    Negative   2.0590         1.3654         2.573
  2-Octenedioic acid                                                                                            HMDB0000341      343.1414    1.7113     Negative   0.0230         1.4765         2.370
  1,2,3,4-Tetrahydro-beta-carboline                                                                             HMDB0012488      515.2876    3.2529     Negative   2.0170         1.1922         1.332
  Methyldopa                                                                                                    HMDB0011754      210.0768    1.6219     Negative   0.0000         2.5799         4.767
  PE\[20:2(11Z,14Z)/24:1(15Z)\]                                                                                 HMDB0009311      834.6232    9.8316     Negative   2.1900         1.8322         5.080
  Glucosylceramide (d18:1/18:0)                                                                                 HMDB0004972      708.6159    10.0221    Negative   2.9864         1.3608         2.665
  *cis-*Hydroxy Perhexiline                                                                                     HMDB60644        585.5305    9.2354     Negative   2.7983         1.3734         2.780
  TG\[18:4(6Z,9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z)/ 18:4(6Z,9Z,12Z,15Z)\]                                        HMDB55513        873.6569    9.7697     Negative   2.8400         1.6794         4.108
  Cinncassiol D1 glucoside                                                                                      HMDB0034677      513.2730    3.3567     Negative   2.4747         1.6398         2.277
  AS 1-5                                                                                                        HMDB0032843      714.5535    8.7898     Negative   2.1915         1.4575         2.933
  Glycochenodeoxycholic acid 3-glucuronide                                                                      HMDB0002579      606.3294    3.1567     Negative   2.5622         1.6289         2.650
  TG\[14:1(9Z)/14:0/14:1(9Z)\]                                                                                  HMDB47724        717.5925    9.4073     Negative   2.1038         1.3365         2.913
  Asparaginyl-Serine                                                                                            HMDB0028740      437.1628    3.6093     Negative   0.4650         1.8095         1.691
  1-non-adecanoyl-glycero-3-phosphate                                                                           HMDB62322        903.5960    9.7766     Negative   2.6135         1.6610         3.764
  Hexahydro-6,7-dihydroxy-5-(hydroxymethyl)-3-(2-hydroxyphenyl)-2H-pyrano\[2,3-d\]oxazol-2-one                  HMDB0029234      278.0648    1.6219     Negative   0.0001         2.5755         4.609
  PE\[DiMe(13,5)/MonoMe(13,5)\]                                                                                 HMDB61496        902.6103    9.8316     Negative   3.5042         1.6608         4.153
  (2-hydroxy-2-{9-\[(3-methylbut-2-enoyl)oxy\]-2-oxo-2H,8H,9H-furo\[2,3-h\]chromen-8-yl}propoxy)sulfonic acid   HMDB0001511      421.0596    2.7668     Negative   0.4444         1.6591         1.564
  (2S)-2-amino-3-\[4-hydroxy-3-(sulfooxy)phenyl\]-2-methylpropanoic acid                                        HMDB0142153      290.0342    1.6082     Negative   0.1225         2.1124         2.902
  Asiaticoside                                                                                                  HMDB36656        979.5918    9.9829     Negative   2.2756         1.7261         4.518
  Ponasteroside A                                                                                               HMDB0034091      625.3600    4.2329     Negative   2.2531         1.0898         1.442
  MG(12:0/0:0/0:0)                                                                                              HMDB72863        821.6323    9.9829     negative   2.2034         1.6330         4.102
  7-Chloro-6-demethylcepharadione B                                                                             HMDB0031833      340.0355    1.6219     Negative   0.0001         2.3257         3.726
  Norpropoxyphene                                                                                               HMDB0011627      974.5991    8.7760     Negative   2.3974         1.1448         1.437
  Hordatine B glucoside                                                                                         HMDB0030460      370.1782    4.0679     Negative   0.3956         1.7169         1.856

a

Compound ID was mainly exhibited based on the Human Metabolome Database (

www.hmdb.ca

).

b

FC value was calculated as the ratio of the average mass response (area) between the two groups (FC value = PD/HC). Thus, FC values \>1 indicate significantly higher levels in the PD group relative to the HC group while FC values \<1 indicate significantly lower levels in the PD group.

c

Only metabolites with FC values greater than ±2.0, VIP values greater than 1.0 and p-values less than 0.05 were deemed statistically significant. PD, Parkinson's disease; RT, retention time; FC, fold change; VIP, variable influence on projection; HC, healthy control.

![Multivariate statistical analysis of metabolomics and the classification of differentially expressed metabolites between PD patients and healthy controls. **(A)** PLS-DA score plot derived from liquid chromatography-mass spectrometry-based metabolomics analysis of PD patients and healthy controls. **(B)** Statistical validation of the PLS-DA model by permutation testing with 200 iterations. **(C)** Pie chart of the superclass of chemical taxonomy based on the annotations from Human Metabolome Database. **(D)** Pie chart of the further classification of lipids and lipid-like molecules. PD, Parkinson's disease; HC, healthy control; PLS-DA, partial least squares-discriminant analysis.](fnmol-13-00080-g001){#F1}

The related metabolic pathway is shown in [Figure 2A](#F2){ref-type="fig"}, where only the sphingolipid metabolism pathway is significantly enriched (pathway impact = 0.473, *q*-value = 0.004). All six metabolites involved in sphingolipid metabolism had significantly increased, indicating that the pathway is activated in PD patients ([Figure 2B](#F2){ref-type="fig"}).

![Metabolic pathway analysis based on the differentially expressed metabolites from the metabolomics data using MetaboAnalyst4.0. **(A)** Pathway analysis indicates sphingolipid metabolism is the only statistically enriched pathway. **(B)** In the sphingolipid metabolism pathway there are five differentially expressed metabolites involved, and all of them have increased in patients with Parkinson's disease.](fnmol-13-00080-g002){#F2}

Results of the Proteomics Analysis {#S3.SS2}
----------------------------------

The clinical data of all the participants included in the proteomics analysis are exhibited in [Table 3](#T3){ref-type="table"}. No statistical differences can be observed in these data, indicating that the following comparison of the two groups was reasonable. A total of 912 proteins were identified in plasma and protein ratio distributions between the two groups, which are shown in [Figure 3A](#F3){ref-type="fig"}. Forty differentially expressed proteins were recognized, with fifteen proteins increased and twenty-five decreased ([Figure 3B](#F3){ref-type="fig"}). The details of these proteins were shown in [Table 4](#T4){ref-type="table"} and the seven differentially expressed apolipoproteins (apolipoprotein C-I, apolipoprotein C-III, protein APOC4-APOC2, apolipoprotein C-IV, apolipoprotein B variant, apolipoprotein B, and apolipoprotein M) were all significantly decreased.

###### 

Clinical data of PD patients and healthy controls included in the tandem mass tag-based proteomics analysis.

  Variable (SEM/%)           HC (27)        PD (30)        *p*-value   Variable (SEM/%)   HC (27)          PD (30)          *p*-value
  -------------------------- -------------- -------------- ----------- ------------------ ---------------- ---------------- -----------
  Age (year)                 66.59 ± 1.14   69.17 ± 1.50   0.184       HbA1c (%)          5.99 ± 0.18      6.17 ± 0.19      0.515
  Gender, Male (%)           14 (51.9%)     19 (63.3%)     0.381       TC (mmol/L)        4.33 ± 0.17      4.32 ± 0.16      0.952
  Smoking history (%)        9 (33.3%)      7 (23.3%)      0.402       TG (mmol/L)        1.49 ± 0.15      1.23 ± 0.14      0.206
  Alcohol consumption (%)    3 (11.1%)      1 (3.3%)       0.53        HDL-C (mmol/L)     1.21 ± 0.08      1.24 ± 0.09      0.858
  Hypertension (%)           15 (55.6%)     13 (43.3%)     0.357       LDL-C (mmol/L)     2.81 ± 0.15      2.73 ± 0.13      0.679
  Diabetes mellitus (%)      2 (7.4%)       5 (16.7%)      0.51        Apo-A1 (g/L)       1.31 ± 0.05      1.30 ± 0.05      0.93
  Hypercholesterolemia (%)   4 (14.8%)      6 (20.0%)      0.869       Apo-B (g/L)        0.89 ± 0.04      0.85 ± 0.04      0.403
  BMI (kg/m2)                23.95 ± 0.69   22.79 ± 0.58   0.197       Lpa (mg/L)         201.19 ± 48.58   270.04 ± 66.49   0.407
  UPDRS score                /              38.49 ± 3.98   /           Hoehn-Yahr score   /                2.40 ± 0.16      /

PD, Parkinson's disease; SEM, standard error of the mean; HC, healthy control; HbA1c, hemoglobin A1c; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Apo-A1, apolipoprotein A1; Apo-B, apolipoprotein B; BMI, body mass index; Lpa, lipoprotein a; UPDRS, Unified Parkinson's Disease Rating Scale.

###### 

Key differentially expressed proteins identified by tandem mass tag-based proteomics analysis between PD patients and healthy controls.

  Uniprot ID   Protein name (GeneName)                                                         MW \[kDa\]   FC value^a^   *p*-value^b^
  ------------ ------------------------------------------------------------------------------- ------------ ------------- --------------
  O75339       Cartilage intermediate layer protein 1 (CILP)                                   132.48       1.247         0.003
  A9UFC0       Caspase 14 (CASP14)                                                             27.65        2.077         0.010
  Q5T619       Zinc finger protein 648 (ZNF648)                                                62.30        1.276         0.010
  Q04756       Hepatocyte growth factor activator (HGFAC)                                      70.64        1.605         0.013
  Q9UQ05       Potassium voltage-gated channel subfamily H member 4 (KCNH4)                    111.62       1.213         0.014
  E5RIF9       Carbonic anhydrase 1 (CA1)                                                      16.31        1.230         0.021
  P01023       Alpha-2-macroglobulin (A2M)                                                     163.19       1.251         0.025
  B7Z544       cDNA FLJ51742, highly similar to Inter-alpha-trypsin inhibitor heavy chain H4   98.29        1.206         0.026
  Q6UWP8       Suprabasin (SBSN)                                                               60.50        1.230         0.028
  A0A087WYF1   Laminin subunit alpha-2 (LAMA2)                                                 343.20       1.254         0.030
  P04275       von Willebrand factor (VWF)                                                     309.06       1.210         0.031
  D3DQX7       Serum amyloid A protein (SAA1)                                                  13.55        1.264         0.032
  A0A125U0U7   MS-C1 heavy chain variable region                                               13.09        1.210         0.039
  Q96K23       cDNA FLJ14838 fis, clone OVARC1001726, weakly similar to APICAL-LIKE PROTEIN    27.99        1.380         0.041
  D6RF20       Vitamin D-binding protein(GC)                                                   16.07        1.255         0.046
  P02656       Apolipoprotein C-III (APOC3)                                                    10.85        0.718         0.001
  Q1W658       Follicle-stimulating hormone beta subunit (FSHB)                                8.45         0.331         0.002
  K7ER74       Protein APOC4-APOC2 (APOC4-APOC2)                                               20.04        0.661         0.002
  Q04695       Keratin, type I cytoskeletal 17 (KRT17)                                         48.08        0.465         0.003
  Q5NV68       V4-1 protein (V4-1)                                                             11.23        0.342         0.005
  Q59HB3       Apolipoprotein B variant                                                        183.46       0.832         0.007
  P04259       Keratin, type II cytoskeletal 6B (KRT6B)                                        60.03        0.611         0.008
  K7ERI9       Apolipoprotein C-I (APOC1)                                                      8.64         0.710         0.009
  G5E968       Chromogranin A (CHGA)                                                           34.25        0.786         0.009
  Q99592       Zinc finger and BTB domain-containing protein 18 (ZBTB18)                       58.32        0.830         0.009
  P10720       Platelet factor 4 variant (PF4V1)                                               11.55        0.778         0.010
  O95445       Apolipoprotein M (APOM)                                                         21.24        0.831         0.011
  A0A0G2JPR0   Complement C4-A (C4A)                                                           192.75       0.620         0.012
  Q99857       Tenascin-C                                                                      9.76         0.818         0.013
  Q07507       Dermatopontin (DPT)                                                             23.99        0.724         0.015
  O95576       Pepsinogen                                                                      8.71         0.820         0.015
  C0KRQ8       Glycoprotein hormones alpha chain (CGA)                                         10.20        0.542         0.016
  P55056       Apolipoprotein C-IV (APOC4)                                                     14.54        0.817         0.020
  P35908       Keratin, type II cytoskeletal 2 epidermal (KRT2)                                65.39        0.827         0.033
  E1B4S7       Apolipoprotein B (APOB)                                                         25.22        0.831         0.034
  P80108       Phosphatidylinositol-glycan-specific phospholipase D (GPLD1)                    92.28        0.785         0.034
  H7C0N0       Inter-alpha-trypsin inhibitor heavy chain H1 (ITIH1)                            51.83        0.811         0.039
  H7BZ76       Latent-transforming growth factor beta-binding protein 1 (LTBP1)                28.80        0.806         0.040
  Q7RTS7       Keratin, type II cytoskeletal 74 (KRT74)                                        57.83        0.807         0.040
  B2RCB8       cDNA, FLJ95971, highly similar to Homo sapiens protocadherin 12 (PCDH12)        128.91       0.819         0.044

a

FC value was calculated as the ratio of the average mass response (area) between the two groups (FC value = PD/HC). Thus, FC values \>1 indicate significantly higher levels in the PD group relative to the HC group while FC values \<1 indicate significantly lower levels in the PD group.

b

Only proteins with FC values greater than ± 1.2 and p-values less than 0.05 were deemed statistically significant. PD, Parkinson's disease; MW, molecular weight; FC, fold change; HC, healthy control.

![The exhibition of whole proteins detected in plasma and the differentially expressed proteins between PD patients and healthy controls. **(A)** Protein ratio distribution, **(B)** volcano plot showed FC values and *p*-values of all the identified proteins. Red dots represent increased differentially expressed proteins while green dots represent decreased proteins. FC value was calculated as the ratio of the average mass response area between the two groups (FC value = PD/HC). *p*-Value was calculated using Mann-Whitney *U*-test. PD, Parkinson's disease; HC, healthy control; FC, fold change. Blue dots represent unchanged proteins. The horizonal red dashed lines indicate a *p*-value \< 0.05 while the vertical red dashed lines indicate FC = 0.](fnmol-13-00080-g003){#F3}

There were 162, 25, and 22 GO terms significantly associated with biological processes, cellular components, and molecular function, respectively. The top 20 GO terms from GO enrichment analysis are shown in [Figure 4](#F4){ref-type="fig"} and [Table 5](#T5){ref-type="table"}. Five of the six top ranked GO terms from cellular components (very-low-density lipoprotein particle, triglyceride-rich lipoprotein particle, lipoprotein particle, plasma lipoprotein particle, and protein-lipid complex) were directly associated with lipids. The remaining top ranked GO term from cellular components was keratin filament. Eleven of the fourteen top ranked GO terms from biological processes were directly associated with lipid metabolism. These were regulation of very-low-density lipoprotein particle clearance, negative regulation of very-low-density lipoprotein particle clearance, regulation of the fatty acid biosynthetic process, regulation of lipoprotein particle clearance, regulation of the fatty acid metabolic process, negative regulation of lipoprotein particle clearance, the lipid metabolic process, protein--lipid complex remodeling, plasma lipoprotein particle remodeling, protein--lipid complex subunit organization, and plasma lipoprotein particle organization. The remaining three GO terms were negative regulation of receptor-mediated endocytosis, organic hydroxyl compound transport, and macromolecular complex remodeling. They were also indirectly associated with lipid metabolism because all of the involved proteins were lipoproteins.

###### 

The top 20 most enriched GO terms and involved proteins based on proteomics analysis between PD patients and healthy controls.

  Go terms                                                                 Category   Involved proteins                                                                        *q*-value   Rich factor
  ------------------------------------------------------------------------ ---------- ---------------------------------------------------------------------------------------- ----------- -------------
  Very-low-density lipoprotein particle                                    CC         O95445, K7ER74, P55056, Q59HB3, P02656, K7ERI9, E1B4S7                                   0.021       0.292
  Triglyceride-rich lipoprotein particle                                   CC         O95445, K7ER74, P55056, Q59HB3, P02656, K7ERI9, E1B4S7                                   0.021       0.292
  Keratin filament                                                         CC         P04259, P35908, Q04695, Q7RTS7                                                           0.030       0.500
  Lipoprotein particle                                                     CC         O95445, K7ER74, P55056, P02656, K7ERI9, Q59HB3, E1B4S7                                   0.030       0.206
  Plasma lipoprotein particle                                              CC         O95445, K7ER74, P55056, P02656, K7ERI9, Q59HB3, E1B4S7                                   0.030       0.206
  Protein-lipid complex                                                    CC         O95445, K7ER74, P55056, P02656, K7ERI9, Q59HB3, E1B4S7                                   0.030       0.206
  Negative regulation of receptor-mediated endocytosis                     BP         K7ER74, P02656, K7ERI9                                                                   0.021       1.000
  Regulation of very-low-density lipoprotein particle clearance            BP         K7ER74, P02656, K7ERI9                                                                   0.021       1.000
  Negative regulation of very-low-density lipoprotein particle clearance   BP         K7ER74, P02656, K7ERI9                                                                   0.021       1.000
  Regulation of fatty acid biosynthetic process                            BP         K7ER74, P02656, K7ERI9                                                                   0.030       0.750
  Regulation of lipoprotein particle clearance                             BP         K7ER74, P02656, K7ERI9                                                                   0.030       0.750
  Regulation of fatty acid metabolic process                               BP         K7ER74, P02656, K7ERI9                                                                   0.030       0.750
  Negative regulation of lipoprotein particle clearance                    BP         K7ER74, P02656, K7ERI9                                                                   0.030       0.750
  Organic hydroxy compound transport                                       BP         O95445, K7ER74, G5E968, Q59HB3, P02656, K7ERI9, E1B4S7                                   0.030       0.212
  Lipid metabolic process                                                  BP         O95445, Q1W658, O75339, K7ER74, P55056, P02656, K7ERI9, Q59HB3, D6RF20, E1B4S7, P80108   0.030       0.133
  Protein-lipid complex remodeling                                         BP         O95445, K7ER74, P02656, K7ERI9, Q59HB3, E1B4S7                                           0.030       0.240
  Plasma lipoprotein particle remodeling                                   BP         O95445, K7ER74, P02656, K7ERI9, Q59HB3, E1B4S7                                           0.030       0.240
  Protein-lipid complex subunit organization                               BP         O95445, K7ER74, P02656, K7ERI9, Q59HB3, E1B4S7                                           0.030       0.240
  Plasma lipoprotein particle organization                                 BP         O95445, K7ER74, P02656, K7ERI9, Q59HB3, E1B4S7                                           0.030       0.240
  Macromolecular complex remodeling                                        BP         O95445, K7ER74, P02656, K7ERI9, Q59HB3, E1B4S7                                           0.030       0.240

GO, gene ontology; PD, Parkinson's disease; CC, cellular component; BP, biological process.

![The top 20 most enriched GO terms based on proteomics analysis between PD patients and healthy controls. Five of the six top ranked GO terms from the cellular component and eleven of the 14 top ranked GO terms from the biological process were directly associated with lipid metabolism. BP, biological process; CC, cellular component; GO, gene ontology; PD, Parkinson's disease.](fnmol-13-00080-g004){#F4}

These differentially expressed proteins were also mapped to KEGG pathways and enriched in five pathways with *p*-values less than 0.05 ([Table 6](#T6){ref-type="table"}), including ovarian steroidogenesis, the GnRH signaling pathway, neuroactive ligand--receptor interaction, glycosylphosphatidylinositol (GPI)-anchor biosynthesis, and regulation of lipolysis in adipocytes. However, no significant differences can be observed after being adjusted by Benjamini-Hochberg correction (*q*-value \> 0.05), indicating that these results were unstable.

###### 

Enriched KEGG pathways and involved proteins based on proteomics analysis between PD patients and healthy control.

  Enriched KEGG pathway                                    Involved protein   *p*-value   *q*-value   Rich factor
  -------------------------------------------------------- ------------------ ----------- ----------- -------------
  Ovarian steroidogenesis                                  Q1W658 C0KRQ8      0.005       0.134       0.667
  GnRH signaling pathway                                   Q1W658 C0KRQ8      0.025       0.217       0.333
  Neuroactive ligand-receptor interaction                  Q1W658 C0KRQ8      0.034       0.217       0.286
  Glycosylphosphatidylinositol (GPI)-anchor biosynthesis   P80108             0.043       0.217       1
  Regulation of lipolysis in adipocytes                    C0KRQ8             0.043       0.217       1

KEGG, Kyoto Encyclopedia of Genes and Genomes; PD, Parkinson's disease.

Discussion {#S4}
==========

Systemic biology is the most useful way to overview the metabolic alterations of an organism in a pathological condition. Here, we have adopted an integrated metabolomics and proteomics analysis of plasma in PD patients to explore its potential pathogenesis for the first time. No significant differences were found in any of the clinical data between these two groups, suggesting the following omics analyses were reasonable.

Researchers from the United States performed the first metabolomics profiling of plasma in PD patients ([@B4]). They identified altered levels of 8-hydroxy-2-deoxyguanosine, uric acid, and glutathione as potential blood biomarkers for PD patients without further pathway analysis. Other researchers also performed metabolomics analysis of cerebrospinal fluid ([@B30]) and urine ([@B31]) from PD patients, suggesting various perturbed metabolic pathways related to lipids, energy, fatty acids, bile acids, polyamine, and amino acids ([@B36]). In this untargeted metabolomics analysis, significant metabolic differences were found between PD patients and healthy controls from the PLS-DA plot. Eighty-three differentially expressed metabolites were identified between the two groups, most of which were lipid and lipid-like molecules. The lipid and lipid-like molecules were further classified, and sphingolipids accounted for 25%. Furthermore, pathway analysis indicated that sphingolipid metabolism was the only significantly enriched metabolic pathway, and the pathway tended to be activated. Sphingolipids are a class of lipids containing a backbone of sphingoid bases and a set of aliphatic amino alcohols (e.g., ceramides, sphingomyelins, gangliosides, and cerebrosides). The involvement of sphingolipid metabolism was first reported in a yeast model of Parkinson's disease ([@B28]). The *Saccharomyces cerevisiae* lipid elongase null mutants exhibited severe growth defects, accumulation of reactive oxygen species, aberrant protein trafficking, and a dramatic decrease in the survival of aged cells. α-Synuclein (α-syn) is a small soluble synaptic protein that is the major proteinaceous component of Lewy bodies, the pathological hallmark of Parkinson's disease ([@B24]). It was reported that the toxicity of α-syn could be enhanced as a result of the disruption of ceramide-sphingolipid homeostasis in the endoplasmic reticulum ([@B28]). Whereas Gaucher disease-related sphingolipids (glucosylceramide, glucosylsphingosine, sphingosine, sphingosine-1-phosphate) are reported to induce α-syn aggregation, glucosylsphingosine can trigger the formation of oligomeric α-syn in human neurons ([@B39]). Autophagy can be impaired by the increased levels of glucosylceramide and sphingomyelin while also enhanced by the increased levels of ceramide ([@B23]). In total, the disruption of the sphingolipid metabolism leads to α-syn accumulation, influences the traffic of vesicles toward lysosomes, and affects autophagy. Mutations of glucocerebrosidase 1, an enzyme hydrolyzing glucocerebroside (a subclass of sphingolipids), are the most common genetic risk factor for PD, although the underlying biological processes are poorly understood ([@B20]). Metabolomics analysis mainly focuses on small molecules (\<1 KD), and in this research a proteomics analysis was further performed.

A lot of proteomics research has been conducted in PD patients, mainly from brain tissues (substantia nigra, thalamus, locus coeruleus, olfactory bulb, and cerebral cortex), biofluids (cerebrospinal fluid, tears, and blood) and subcellular structures (mitochondria) ([@B9]). Most of this research referred to pathways involved in "mitochondrial dysfunction, oxidative stress, protein aggregation or degradation, autophagy, and inflammation"([@B35]; [@B33]). Here, forty proteins were differentially expressed in PD patients from the plasma proteomics analysis and the levels of all the seven apolipoproteins (apolipoprotein C-I, apolipoprotein C-III, protein APOC4-APOC2, apolipoprotein C-IV, apolipoprotein B variant, apolipoprotein B, and apolipoprotein M) were significantly decreased. Another former study reported decreases of apolipoprotein AII and apolipoprotein E in Parkinson's disease ([@B42]). The decrease of apolipoprotein B-100 ([@B29]) and apolipoprotein A-I ([@B43]) was also reported in some studies. There are a large number of lipids in the central nervous system, and about one-fourth of the total cholesterol has a function or is stored in the brain. These apolipoproteins can influence the deposition process of many proteins in neurodegenerative diseases, such as α-syn in PD ([@B43]). According to the enriched GO analysis, five of the six top ranking GO terms from cellular components were directly associated with lipids, and eleven of the fourteen top ranking GO terms from biological processes were directly associated with lipid metabolism. Keratin filament from the cellular component is a part of the intermediate filament and constitutes the cytoskeleton while Lewy bodies are the accumulation of neurofilaments (intermediate filament) in Parkinson's disease. The underlying pathogenesis needs further research to confirm. The remaining three GO terms from biological processes were also related with lipid metabolism, as all the involved proteins were lipoproteins. KEGG pathway analysis was performed with those differentially expressed proteins and it seemed to be enriched in five pathways. The GnRH signaling pathway and ovarian steroidogenesis directly regulate steroid hormones and participate in the production of steroids. These processes belong to neuroactive ligand--receptor interaction. Glycosylphosphatidylinositol (GPI)--anchor biosynthesis and regulation of lipolysis in adipocytes are direct detailed processes of lipid metabolism. However, the results were unstable after Benjamini-Hochberg correction, as no significant differences could be observed (*q*-value \> 0.05).

Both sphingolipids and apolipoproteins participate in plasma lipid metabolism, and are mainly related with atherosclerotic diseases. A number of lipidomics studies have reported specific lipid alterations in the brain or plasma from PD patients, such as the composition alteration of lipid rafts in the frontal cortex ([@B1]). The interaction of α-syn and the synaptic membrane is thought to be critical in Parkinson's disease and has been explored for many years ([@B26]). It is reported that lipids and the ratio of lipids to proteins can regulate the aggregation propensity of α-syn ([@B18]). α-Syn can interact with the lipid membrane, and that interaction further affects the oligomerization and aggregation of α-syn ([@B38]). The alteration of lipid chemical properties can also induce α-syn aggregation and affect the balance between functional and aberrant behavior of α-syn ([@B19]). In addition, α-syn can bind to specific lipid molecules, and these lipid--protein conjugates can further help the transport of α-syn in the blood or across the blood-brain barrier ([@B16]), enhance its interaction with synaptic membranes, and interfere with the catalytic activity of cytoplasmic and lysosomal lipases, thereby disrupting lipid metabolism ([@B1]). In the meantime, lipid dysregulation can also promote PD pathogenesis through oxidative stress and inflammation reaction. Apolipoprotein M can increase the level of circulating sphingosine 1-phosphate, activate the following signaling pathway, and induce inflammation reaction ([@B27]). Platelet activating factors, a lipid proinflammatory mediator, play an important role in modulating progressive neurodegeneration in PD patients by intracellular trafficking of α-syn. Furthermore, there are a large number of genetic risk factors of PD involved in lipid metabolism, including *PLA2G6* and *SCARB2*. These two genes are directly or indirectly involved in glycerophospholipid and sphingolipid metabolism ([@B1]). Mutations in the glucocerebrosidase 1 gene, which encodes a degrading enzyme for the glycolipid glucosylceramide, are regarded as strong risk factors for PD and dementia with Lewy bodies, and glucosylceramide has been confirmed to promote toxic conversion of α-syn. Moreover, pathological research has demonstrated the existence of α-syn in the brains of patients with lysosomal storage disorders, in which glycosphingolipids is found to be accumulated ([@B38]). In addition, α-syn can antagonize neurotrophic signaling of TrkB by repressing TrkB lipid raft distribution, decreasing its internalization, and reducing its axonal trafficking ([@B25]). The possible pathogenesis is that α-syn sequesters the early peroxidation products of fatty acids, thereby reducing the level of highly reactive lipid species ([@B7]). All in all, dysregulated lipid metabolism is implicated in Parkinson's disease, which might open a new therapeutic method for modifying Parkinson's disease.

Conclusion {#S5}
==========

Integrated proteomics and metabolomics analysis reveals that Parkinson's disease is associated with plasma lipid metabolic disturbance. The activated sphingolipid metabolism and decreased apolipoproteins are the probable potential pathogenesis for PD.
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